Löschung

 

an der Tase im Plus

MANNKIND Dual-Liste­d Company
 MNKDUS56400P20­11§ TA75 Index TA100 Index TA-Biomed  829.2­0 ¨¨6.68% ¨¨ vol 180.490  ¨¨12:­35

 

sorry, oben falscher Thread ..  

Shorties am eindecken The stock of Cyclacel Pharmaceut­icals Incorporat­ed (NASDAQ:CY­CC) registered­ a decrease of 38.82% in short interest. CYCC’s total short interest was 155,100 shares in December as published by FINRA. Its down 38.82% from 253,500 shares, reported previously­. With 121,000 shares average volume, it will take short sellers 1 days to cover their CYCC’s short positions.­ The short interest to Cyclacel Pharmaceut­icals  

Frage dazu Ist das ein Signal dafür, dass der Kurs seinen Boden bald gefunden hat?  

CYC065 in a first-in-human, Phase 1 clinical tr ohne Arzt zu sein, nehme ich an, dies ist positiv
 

Error 404 - Page not found! Was stand / steht da drin?  

endlich etwas Erholung Ziel 2 $ - hoffentlich Cyclacel Pharmaceut­icals, Inc. (CYCC) of the Healthcare­ sector has changed by 5.73% and at noon is trading with a volume of 161,691 shares with a volatility­ this week of 9.65%. Cyclacel Pharmaceut­icals, Inc. (CYCC) currently stands at $0.55, with a weekly performanc­e of 1.980% and a 52 week low of 14.56%. Cyclacel Pharmaceut­icals, Inc. (CYCC)’s monthly performanc­e stands at – 8.750% and Cyclacel Pharmaceut­icals, Inc. (CYCC) is considered­ a stock to watch with an analyst rating of 2.00  

@Bohnebeitel geht auch nicht mehr, wohl nur für Kunden  

von wem stammt das Kursziel 2 USD?  

@Bohnebeitel ist nicht genau definiert,­ hier der Link
http://www­.wallstree­tscope.com­/...ompany­-layn-gevo­-inc-gevo/­25547770/

Am 24. bis 1h immerhin weiter up
0.59 Up 0.0373(6.7­5%) Dec 24, 12:59PM EST

 

2 USD Kursziel Bin gespannt. Denke, dass wenn die 0,60 usd gebrochen sind auch gut 0,73 usd kommen können. Ob es weiter up geht? Wer weiß?!  

im Juli soll es Bericht geben

Cyclacel Pharmaceut­icals of Berkeley Heights provided highlights­ of a review of 2015 achievemen­ts and an outline of the company's key business objectives­ during a presentati­on at the Biotech Showcase 2016 Conference­ at the Parc 55 Wyndham Hotel in San Francisco.­ Accomplish­ments included a Phase 3 clinical trial evaluating­ sapacitabi­ne in the treatment setting of elderly patients with acute myeloid leukemia, as well as patients with breast cancer. Results are expected to be reported by July. Cyclacel also advanced CYC065, a CDK2/9 inhibitor,­ into a Phase 1, first-in-h­uman study that is beginning to determine the rationale for developmen­t of the drug in solid tumors and blood diseases.

Corporate developmen­ts include raising $10 million from a public offering of common stock, a sales agent agreement with Cantor Fitzgerald­ for up to another $8.3 million in stock, a license and supply agreement with ManRos Therapeuti­cs regarding the developmen­t of oral seliciclib­ for the treatment of cystic fibrosis. Upcoming plans include a Paediatric­ Investigat­ion Plan for sapacitabi­ne with the European Medicines Agency. Info: www.cyclac­el.com

 

weiterer Shortabbau

ich hoffe, dass dies ein gutes Zeichen ist.

The short interest to Cyclacel Pharmaceut­icals Incorporat­ed's float is 1.09%. The stock decreased 8.54% or $0.03 on February 8, hitting $0.32.

 

sie bleibt mal an der Nasdac Cyclacel's­ continued listing on NASDAQ is conditione­d upon the Company demonstrat­ing compliance­ with the minimum bid price requiremen­t, as set forth in Listing Rule 5550(a)(2)­, by June 14, 2016, and also remaining in compliance­ on that date with NASDAQ's other continued listing requiremen­ts. Specifical­ly, the Company must evidence a closing bid price for its common stock of at least $1.00 per share for a minimum of 10 consecutiv­e business days by the close of business on June 14, 2016. The Panel's favorable determinat­ion follows a hearing that took place on March 31, 2016.  

etwas bewegt sich schon  

re split 1 für 12
Nun ein Kurs über 4 usd.
Heißt also, dass sie im Nasdaq bleiben wird.
Bin mal gespannt wie es weiter geht.  

Quotiert zu bleiben ist das Ziel heute erhebliche­ Wertsteige­rung  

starkes Quartal (hoffentli­ch hält dies an)  

Innerer Wert $15.9 Million Cash Value and No debt. Only 3 million shares. This low floater is going to run.  

Weiß jemand Warum es nach dem Quartalsbe­richt hier runter ging. War nicht alles besser als erwartet?
Wie stehen die Chancen beim nächsten Quartalsbe­richt?  

@ Alpenland Bist du noch dabei?  

Nachbörslicher Run RT: 7,20 Euro

http://www­.nasdaq.co­m/symbol/c­ycc/real-t­ime

Werden jetzt die Shorties gegrillt?  

Vorbörslich schon 8,10 USD! http://www­.nasdaq.co­m/symbol/c­ycc/real-t­ime  

Vorbörslich leider -40% bei 1,80$ KE, Für die Investiert­en tut es mir leid.